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The treatment of early breast cancer (EBC) is becoming
increasingly complex, but also more effective as a better
understanding of cancer biology is achieved with evolving re-
search. Longer follow-up of prospective trials is crucial to
evaluate the impact of current standard treatments in long-
term outcome and safety. In this review we will summarise
the current evidence for optimal treatment of EBC.2. Which EBC patients can safely avoid
adjuvant chemotherapy?
In the 1980s there were substantial advances in the treatment
of breast cancer (BC), and the results of several large random-
ised trials indicated that adjuvant systemic therapy could de-
crease breast-cancer mortality by about 20%. In fact, the
widespread application of adjuvant systemic therapy is con-
sidered the main cause for the declining breast cancer mor-
tality observed in the Western world.
Treatment decisions are based on clinical (biological age,
comorbidities, performance status) and pathological variables
– tumour size, lymph-node status, histological grade, oestro-
gen receptor (ER), progesterone receptor (PR), HER2 and prolif-
eration – that can be combined in the form of algorithms (e.g.
Adjuvant!Online, Nottingham prognostic index) and form the
basis of treatment for guidelines such as the ones from the
European Society for Medical Oncology (ESMO), the National
Comprehensive Cancer Network (NCCN), and St Gallen. How-
ever, it is clear that still too many patients receive this therapy
with little likelihood of benefit and substantial toxicity.
In this section, available data on biomarkers and molecu-
lar tests related to prognostication will be reviewed. In the
first part we will address the evidence and utility for adjuvant
treatment decisions of biomarkers of proliferation (namely
Ki67) and urokinase plasminogen activator (uPA)/plasmino-
gen activator inhibitor (PAI-1). In the second part we willassess the practical contribution of gene expression profiling
in breast cancer.
2.1. Biomarkers
2.1.1. Markers of proliferation – Ki67
Uncontrolled proliferation is a driver for cancer and is one of
the hallmarks of this disease. In general, markers of an ele-
vated proliferative rate correlate with a worse prognosis in
untreated patients and may add predictive information
regarding benefit from chemotherapy (CT) [1]. The most com-
monly used method to measure proliferation involves immu-
nohistochemical (IHC) detection of the nuclear non-histone
protein ki67, which is detected only in proliferating cells.
Ki67 expression is commonly assessed using the mindbomb
E3 ubiquitin protein ligase 1 antibody (MIB1) and reported as
a percentage of cells positive for Ki67.
2.1.2. Prognostic marker
Various studies have investigated the role of Ki67 as a prog-
nostic marker. In a meta-analysis of 40 studies, involving over
11,000 patients, baseline Ki67 was found to have a modest
prognostic value in multivariable analysis, which was more
evident in lymph-node-negative patients [2]. In another
meta-analysis of 46 studies including over 12,000 patients,
Ki67 positivity (using cut-offs defined by individual authors)
was associated with a higher risk of relapse and a worse sur-
vival in patients with EBC [3]. One must highlight several lim-
itations of these data: namely the facts that these are
retrospective studies, many include heterogeneous groups
of patients who were treated and followed in various ways
that are often incompletely documented, and ki67 methodol-
ogy and cutoff varied widely.
The clinical utility of Ki67 as a prognostic marker is more
apparent when it is considered within more narrowly defined
tumour subgroups and/or as part of a multiparameter panel
of biomarkers, as for example in the IHC4 [4]. Other investiga-
tors have reported that Ki67 is an important part of a prognostic48 Lisbon,
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ole or tamoxifen [5].
2.1.3. Predictive marker
Studies have focused on the predictive value of this bio-
marker regarding benefit from CT or even from specific CT
agents. In the ER-positive BC the results are contradictory.
In the recently reported PACS 001 and BCIRG 001, high levels
of Ki67 were predictive of benefit from adding docetaxel to
fluorouracil, epirubicin and cyclophosphamide (FEC) CT as
adjuvant treatment [6]. However, these results contrast with
those from the International Breast Cancer Study Group Trials
(IBCSG) VIII and IX that found no predictive value of Ki67 lev-
els for the addition of cyclophosphamide, methotrexate and
fluorouracil (CMF) to endocrine therapy (ET) in endocrine-
responsive node-negative disease [7]. For ER-negative BC data
to suggest that Ki67 predicts adjuvant chemotherapy re-
sponse are scarce. However, taking into account all the avail-
able evidence that these tumours as a group are more
responsive to chemotherapy than ER-positive tumours [8,9],
one can hypothesise that higher chemotherapy sensitivity ob-
served in patients with ER-negative tumuors is at least par-
tially due to the consistently higher rates of proliferation of
these tumours. If so, Ki67 levels may be helpful in identifying
those patients most likely to benefit from chemotherapy [10].
In spite of consistent data on Ki67 as a prognostic marker
in early breast cancer, its role in breast cancer management
remains uncertain [11], mainly because of the lack of stan-
dardisation. In 2007 the ASCO Tumour Marker Guidelines sta-
ted that evidence supporting the clinical utility of Ki67 was
insufficient to recommend its routine use for prognostic pur-
poses in patients with newly diagnosed breast cancer [12].
However, in the St Gallen Consensus guidelines from 2011
[13] and 2013 most panelists recommend the use of Ki67 for
BC subtyping classification, prognostication and prediction
of response to CT, although there is no consensus on the best
cut-off to be used.
The limitations of this assay are largely related to the dif-
ficulty in interpreting the literature due to lack of standardisa-
tion of assay reagents, procedures and scoring. To overcome
these constraints in 2011 the International Ki67 in Breast Can-
cer Working Group published recommendations for Ki67
assessment in breast cancer [14]. These guidelines aim to
minimise pre-analytical and analytical variables in Ki67
assessment and harmonise scoring methodology and data
handling, facilitating its routine use in clinical practice.
2.1.4. Urokinase plasminogen activator/plasminogen
activator inhibitor
uPA and PAI-1 biomarkers are invasion biomarkers analysed
by a protein-based enzyme-linked immunosorbent assay (ELI-
SA). They can be used to determine the recurrence risk in pa-
tients with node-negative EBC with the aim of better refining
the decision to recommend CT in this patient population.
uPA is a serine protease with an important role in cancer
invasion and metastases [15]. When bound to its receptor
(uPAR), uPA converts plasminogen into plasmin and mediates
degradation of the ECM during tumour-cell invasion. PAI-1
levels are high in tumour tissue and plasma, and PAI-1 is inac-
tivated when bound to uPA.Several retrospective studies [16,17] and a large pooled
analysis of individual patient data from 8377 women treated
in clinical trials by the European Organisation for the Re-
search and Treatment of Cancer (EORTC) [18], in which tu-
mour uPA and PAI-1 levels were determined in primary
tumour tissue extracts, proved that high levels of uPA, uPAR,
and PAI-1 are associated with shorter survival in women with
both node-negative and node-positive disease.
The Chemo N0 is a prospective, multicentre randomised
trial in which researchers stratified patients with node-nega-
tive BC into two groups according to the presence of low or
high uPA/PAI-1 values. Those with low values of both uPA
and PAI-1 received observation only, whereas those with high
uPA and/or PAI-1 values were randomised to receive either
CMF or observation. The 10-year follow-up updated analysis
showed that: low-risk N0 patients according to the uPA/PAI-
1, thus without any systemic therapy, had an excellent prog-
nosis, with a 10-year survival rate of almost 90% [19], while
the high-risk patients according to the uPA/PAI-1 had a 1.84-
fold higher disease recurrence risk (P = 0.017) than the low-
uPA/PAI-1. Additionally, the assay predicted, in the high-risk
population, the benefit from CT [20]. These results provide
for the first time long-term follow-up from a prospective bio-
marker-driven clinical trial in cancer.
The Node-Negative Breast Cancer (NNBC)-3 study is a pro-
spective multicentre phase III therapy trial, with the aim of
comparing risk assessment and clinical outcome on the basis
of tumour-biological factors uPA/PAI-1 with those based on
established, clinical and pathomorphological factors in
high-risk node-negative BC patients. It enrolled more than
4000 patients, stratified into low-risk and high-risk groups
according to the uPA/PAI-1 value or according to the clinical
pathological algorithm. Those classified as low risk did not re-
ceive CT, whereas those classified as high risk received either
six cycles of FEC or three cycles of FEC and three cycles of
docetaxel [21]. In the West German Study Group Plan B trial,
a prospective comparison of recurrence score (RS) – Onco-
typeDx – and independent central pathology assessment of
prognostic tools was performed. The study randomised 2361
patients; 18% had a recurrence score of 0–11 (low risk), 61%
had a recurrence score of 12–25 (intermediate risk), and 21%
had a recurrence score of >25 (high risk). A weak correlation
was found between uPA/PAI-1 and RS. These data showed
that high-risk status according to RS is well correlated with
high risk by uPA/PAI-1; however, there was substantial heter-
ogeneity in risk assessment in the low- and intermediate-risk
RS groups in which some patients are still considered to be
high risk according to uPA/PAI-1 [22].
2.2. Gene-expression-based assays
Gene expression profiling has identified several molecular sig-
natures that mostly have prognostic value and some predic-
tion value.
2.2.1. First-generation prognostic signatures – MammaPrintTM
MammaPrintTM is a microarray-based gene-expression-profil-
ing assay that measures the levels of expression of 70 genes
related to proliferation, invasion and angiogenesis. The assay
accurately categorises patients in poor and good prognosis
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metastases within 5 years. Initially requiring fresh or frozen
samples, it can now be effectively performed in formalin-
fixed paraffin-embedded specimens (FFPE).
The initial data were derived from 78 patients with node-
negative BC, 65 cm, the vast majority of whom had ER-posi-
tive tumours and did not receive adjuvant systemic treatment
[23]. The validation cohort included 295 node-negative pa-
tients, of whom 61 were from the initial study, and confirmed
MammaPrintTM independent prognostic value beyond stan-
dard clinicopathological variables in this patient population
[24]. The TRANSBIG consortium carried out an independent
retrospective validation of MammaPrintTM using samples from
nine European countries, which further confirmed the prog-
nostic value of this tool [25]. Additional validation studies
were performed in node-positive EBC patients [26] and in
HER2+ EBC patients [27].
MammaPrintTM is the first FDA-approved gene-expression-
based assay to be used as a prognostic test in EBC patients.
The clinical utility of this assay is being prospectively evalu-
ated in the large, randomised MINDACT trial that enrolled
6690 EBC N0–N3 patients [28].2.2.2. Oncotype DxTM recurrence score
Oncotype DxTM is a quantitative reverse transcriptase–poly-
merase chain reaction- (qRT–PCR-) based signature that mea-
sures the expression of 21 genes (16 cancer-related and five
reference genes), performed using RNA from FFPE tumour tis-
sues. With this multigene predictor assay a mathematical
function (named recurrence score, RS) aiming at predicting
the risk of distant relapse for patients with ER-positive,
lymph-node-negative breast cancer treated with tamoxifen
was developed based on the analysis of clinical samples from
the NSABP B-20 clinical trial [29]. The RS is a continuous var-
iable, ranging from 0 to 100, which translates into three risk-
group categories: low (RS < 18), intermediate (RS from 18 to
<31) and high (RS < 31).
OncotypeDxTM was then validated in a large cohort of ER-
positive, node-negative, tamoxifen-treated BC patients from
the NSABP-B14 trial [30]. The assay was able to stratify a gen-
erally good prognosis population into distinct subgroups (low,
intermediate, or high score) with different rates of distant
recurrence at 10 years (7%, 14% and 31% respectively. Onco-
typeDxTM RS was shown to be strongly associated with sur-
vival from breast cancer and independent from standard
clinicopathological variables [30,31]. Subsequent analysis re-
vealed that RS also seems to correlate with benefit from che-
motherapy in ER-positive BC [32]. The optimal management
of the intermediate-risk group is being addressed in the TAI-
LORx trial (NCT00310180) in which 11,248 patients with ER-
positive, node-negative breast cancer and intermediate risk
(RS 11–25) were randomly assigned to hormone treatment
either alone or in combination with chemotherapy.
Additional validation studies evaluated OncotypeDxTM in
EBC patients with ER-positive disease treated with AI [33]
and ER-positive node-positive BC patients [34].
The RxPONDER trial will randomise 4000 women with N1
disease and an RS of 625 to endocrine therapy with or with-
out chemotherapy [35].While waiting for MINDACT and TAILORx results, interna-
tional recommendations support the selected use of Mamma-
PrintTM and Oncotype DxTM in the ER + EBC patients in whom
standard clinical/pathological factors are considered insuffi-
cient for adjuvant CT decisions.
2.2.3. PAM50
PAM50 assay provides a risk-of-relapse (ROR) score prognostic
of relapse-free survival for patients with node-negative BC
who did not receive adjuvant systemic therapy [36]. This as-
say is composed of 50 genes (derived from tumour samples
of 220 patients in the training set who had ER-positive or
ER-negative tumours and HER2+ or HER2-negative tumours)
related to proliferation, ER-regulated genes, HER2, and basal
and myoepithelial characteristics. It is compatible with
FFPE-derived RNA or qRT-PCR using FF tissue.
The prognostic ability of the PAM50 has been validated in
an independent test set of 786 patients with ER-positive dis-
ease treated only with adjuvant tamoxifen [37].
An ROR model containing a proliferation component (de-
rived using 11 genes associated with cell-cycle function)
was recently added to the original model.
2.2.4. Genomic grade index
The genomic grade index (GGI) is a gene expression signature
developed to better define histological grade assessment with
the ability to divide classic histological grade into low and
high risk. It was developed to overcome the limitation issues,
namely reproducibility, associated with the histological grade
assessment and was developed using a ‘‘bottom-up’’ ap-
proach whereby 97 genes associated with histological grade
were identified and subsequently related to clinical outcome
[38].
The intrinsic prognostic information of proliferation genes
seems to be better evaluated with the GGI than with classic
histological grade as shown in a population of 570 patients
for which complete recurrence-free survival (RFS) and histo-
logical grade was available [24,39,40]. The GGI was able to fur-
ther stratify the subset of histological grade 2 patients into
two subgroups: a grade 1 gene-like profile and a grade 3
gene-like profile with clearly different rates of relapse. Pa-
tients falling in the HG2-GGI3 category revealed a significantly
higher rate of relapse than the HG2-GG1 (HR = 3.61; confi-
dence interval (CI) 2.25–5.78; P < 0.001). In the overall popula-
tion the GGI was also able to stratify patients into two risk
categories with significant differences in RFS rates (high ver-
sus low risk; HR = 2.83; CI 2.13–3.77; P < 0.001).
In addition to prognostic prediction, the GGI ability to pre-
dict response neoadjuvant CT has also been evaluated [41]. In
a study with 229 tumour samples collected before the begin-
ning of CTwith docetaxel and to fluorouracil, doxorubicin and
cyclophosphamide (FAC) a high GGI was associated with
greater response than low-risk GGI (40% versus 12%;
P < 0.001).
2.2.5. Second generation prognostic signatures – genes related
to immune response
Several studies have recently analysed the prognostic role of
tumour-associated lymphocytes (TIL) in breast cancer, mainly
in the triple-negative subtype [42,43]. A link between increased
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survival has been suggested. The expression of genes related
to immune response has also been shown to provide important
prognostic information in ER-negative and in highly prolifera-
tive ER-positive BC [44–47]. Jointly there is evidence to suggest
that both the concentration of inflammatory infiltrate defined
by IHC and expression of B-cell or plasma-cell metagene de-
fined by microarray-based gene-expression profiling are likely
to provide important prognostic information.
2.2.6. Stroma-related prognostic gene signatures
The development of stroma-related prognostic gene signa-
tures is an evolving field of great scientific interest; however,
independent validation of their prognostic accuracy is still
needed before clinical application.3. Which are the current major challenges
regarding neoadjuvant systemic therapy?
3.1. Advantages of neoadjuvant systemic treatment and
end-points for clinical trials
Neoadjuvant therapy (NT) is the standard of care for women
with locally advanced, inflammatory or inoperable primary
breast cancer (BC) [48–51]. Currently, based on the results of
landmark trials NSABP B-18 and NSABP B-27, NT is mainly
used in operable disease to improve the surgical options, to
determine the response to chemotherapy and to obtain
long-term DFS [52–56].
Pathological complete response (pCR) has been considered
predictive of long-term outcome in several neoadjuvant trials
[57], and this finding has been confirmed in two recent studies
[58,59]. The meta-analysis from the Collaborative Trials in Neo-
adjuvant Breast Cancer [58] included 12 randomised neoadju-
vant trials (n = 13,125) and results have shown that individual
patients who achieved a pCR (ypT0ypN0 or ypT0/isypN0) had
a more favourable long-term outcome. This effect was only
seen in HR+/grade 3, triple-negative and HER2+ tumours and
not in low-grade hormone-receptor-positive tumours. Simi-
larly, in the pooled analysis of seven prospective trials
(n = 6000) published by the German Group [59] pCR was associ-
ated with improved DFS in tumours luminal B/HER2-negative,
HER2+/nonluminal, and triple-negative. These recent data
establish pCR as a surrogate marker for survival but emphasise
that it is not an adequate endpoint for slow proliferative tu-
mours (grade 1 or 2, HR+). Additionally, it was not possible to
determine the magnitude of increase in pCR rates predictive
of superior long-term outcome of a specific therapy of a clini-
cally meaningful improvement in survival [60]. These findings
led the FDA to support certain drug development programmes
throughout NT trials using pCR for accelerated approval [61].
Neoadjuvant trials are also recognised as important research
tools, particularly in the field of biomarkers.3.2. Which chemotherapy and targeted therapy regimens
in the neoadjuvant setting. Are there predictive markers?
Anthracycline/taxane-based CT regimens have been the most
extensively studied in the neoadjuvant setting, but so far nospecific regimen has been found to be clearly superior. Incor-
poration of taxanes has increased the response rates
[54,62,63] with large phase III trials reporting pCR rates of
15–20% [57,64,65]. The studies that have accessed tailoring
treatment to response [63,65–67] have not confirmed a clear
benefit from changing to a non-cross-resistant regimen.
In this regard efforts have been made to study biological
markers predictive of pCR. The integrated meta-analysis [68]
on individual data from the German Breast Group and the
AGO Breast Group, on 6402 patients enrolled in neoadjuvant
trials has shown that a greater chance of pCR was seen in
ER-negative patients (OR 3.2; P < 0.0001), HER2+ disease (OR
2.2; P < 0.0001), higher grade (OR 1.8; P < 0.0001), younger age
(OR 1.3; P = 0.0001), non-lobular type tumours (OR 1.7;
P = 0.001) and smaller tumour size (OR 1.5; P = 0.0006). Fur-
thermore, this group recently published a pooled analysis
assessing the prognostic impact of different definitions of
pCR and the outcome regarding the biological intrinsic breast
cancer subtypes [59]. It was found that pCR was associated
with improved DFS in tumours luminal B/HER2-negative
(P < 0.005), HER2+/nonluminal (P < 0.001) and triple-negative
tumours (P < 0.001) but not in luminal A (P = 0.39) or in lumi-
nal B/HER2+ (P = 0.45) tumours. Despite the fact that tumours
lacking expression of ER have higher pCR, exceeding 40% in
some studies, overall patient survival with this phenotype is
still shorter than in patients with hormone-receptor-positive
disease [9]. However, recent data show that patients with
HER2+/nonluminal and triple-negative disease who achieved
pCR have an excellent prognosis [58,59].
Mutations in p53 were shown not to be predictive of re-
sponse to taxanes in the large randomised multicentric neo-
adjuvant trial EORTC 10994/BIG 1-00 [69]. Some studies have
generated preliminary gene signatures with potential predic-
tive value for docetaxel and paclitaxel plus FAC [70,71] but
these signatures have not yet been validated in subsequent
studies and are not ready for use in clinical practice. More re-
cent studies suggest that prediction of response to a specific
CT agent is different among the different BC subtypes and is
more likely to be achieved by using multifactorial tools
[59,72–75]. HER2 over-expression/amplification predicts re-
sponse to treatment with the monoclonal antibody trast-
uzumab [76], and has also been associated with a better
response to anthracyclines [77,78]. It is uncertain whether
the latter effect is linked to the co-amplification of topoiso-
merase IIa as mixed results have been obtained [78,79]. The
association between HER2+ and response to taxanes sug-
gested in some studies [80] needs to be confirmed with fur-
ther research. In HER2+ disease the incorporation of
trastuzumab (H) into NT chemotherapy regimens is considered
standard of care [57]. The first reported randomised trial from
the MDACC showed a very high pCR rate of 65.2% in patients
treated with trastuzumab (versus 26%) [81,82] which led to a
premature closure of the study. Data from two randomised
phase III studies were subsequently available, the NOAH trial
[83] and the GeparQuattro trial [65,84]. The addition of trast-
uzumab to an anthracycline/taxane-based regimen led to an
improvement in event-free survival at 3 years (HR 0.59;
95%CI: 0.38–0.90) in the NOAH trial and a significant increase
in pCR rate in the GeparQuattro trial (31.7% in HER-2-positive
disease versus 15.7% in HER-2-negative disease).
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gle agent and in combination with trastuzumab in two phase
III studies. In the NeoALTTO study [85], 455 patients were ran-
domly assigned to L, H, or L plus H, given alone initially and
then combined with weekly paclitaxel before surgery. Combi-
nation of L and H yielded a significantly higher pCR rate than
the monotherapy arms. The dual combination was associated
with higher toxicity, mainly diarrhoea and a transient revers-
ible rise in transaminases. In the Geparquinto trial [84] 620
HER2+ patients with operable or locally advanced BC were
randomised to four cycles of epirubicin plus cyclophospha-
mide and four cycles of docetaxel 3 weeks, with either con-
current H or L. The H arm had a significantly higher pCR
(30.3%) compared with L (22.7%). Taken together, the results
of these two studies have led to the recommendation that
lapatinib should not be used as a single (neo)adjuvant anti-
HER2 target outside clinical trials. Furthermore, the lapatinib
monotherapy arm in the large adjuvant ALTTO trial has been
STOPPED and patients in that arm were informed and pro-
posed to receive adjuvant trastuzumab.
Dual-HER2 blockade has also been tested in the NeoSphere
trial [86], a phase II randomised trial designed to test the antitu-
mour activity and tolerability of the combination of docetaxel,
trastuzumab and pertuzumab (THP), compared with trast-
uzumab plus pertuzumab (HP), docetaxel and pertuzumab
(TP) and docetaxel and trastuzumab (TH). The pCR was signifi-
cantly higher (P = 0.014) for the combination of docetaxel with
both anti-HER2 target agents (THP), with good tolerability,
namely cardiac safety. These studies plus two trials in the met-
astatic setting [87,88] represent growing evidence that the dual
blockade of the HER2 receptor has superior efficacy and may
soon become standard of care. Still, it is not known which is
the optimal combination of anti-HER2 agents; the best chemo-
therapy regimen to use with these agents, the role of dual HER2
blockade in combination with endocrine therapy for HER2+
and HR+ BC are among other questions.
Triple-negative phenotype (TNBC) has higher response
rates to NT compared to non-triple-negative tumours in several
studies [59,72,89–91], but only if pCR is obtained can it be trans-
lated into a better prognosis. At the present time, CT is the only
proven therapy for TNBC and international guidelines recom-
mend the use of the same regimens as for non-TNBC, i.e. an
anthracycline/taxane-based regimen. Small studies have sug-
gested that platinums may be particularly effective in this sub-
set, with pCR rates of 54.6% for docetaxel and carboplatin [92],
40% for epirubicin, cisplatin, and fluorouracil followed by
weekly paclitaxel [93], and 80% with cisplatin in a BRCA1 muta-Table 1 – Early Breast Cancer Trialists’ Collaborative Group (EBCT
with no CT in early breast cancer (EBC).
Risk of recurrence Breas
Anthracycline-based regimen versus no CT
RR: 0.73, 95% confidence interval (CI)
Absolute gain: 8%
RR: 0
Abso
Cyclophosphamide, methotrexate and
fluorouracil (CMF) regimen versus no CT
RR: 0.70, 95%CI
Absolute gain: 10.2%
RR: 0
Absotion patient population [94]. However, pCR rates of 20% have
also been reported with neoadjuvant cisplatin monotherapy
[95]. These results need further validation in large randomised
studies, especially in the non-BRCA population.
4. What is the optimal adjuvant chemotherapy
regimen?
4.1. State-of-art regimens according to breast cancer
subtype
So far available data do not allow for different regimen recom-
mendations according to BC subtype. Therefore, the consider-
ations below apply to all subtypes of BC when CT is deemed
necessary, with some specific points for HER2+ EBC.
The rationale and support for adjuvant CT for patients
with BC are derived from many large, randomised trials and
from the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis. In the last update analysis [96] the
use of adjuvant CT, with either an anthracycline-based or a
CMF regimen, was shown to be superior to no treatment in
terms of risk of recurrence, breast cancer, or overall mortality
(Table 1). The application of adjuvant CT translated to an
absolute benefit of 5.0%.
There is no single standard adjuvant chemotherapy regi-
men in the treatment of EBC.
When choosing a particular regimen various factors must
be taken in account: namely the recurrence risk, co-morbid
illness and patient preference. The following discussion is
organised along the lines of debate concerning CT regimens:
anthracyclines versus CMF and anthracyclines versus
taxanes.
4.2. Anthracyclines versus CMF
Several randomised trials and the EBCTCG overview (Table 2)
support the superior efficacy of anthracycline-based regimens
over CMF with level I based evidence. However, some caveats
must be highlighted. In the 2011 Oxford Overview anthracy-
cline-based regimens were divided into standard doses (e.g.
cumulative doses of 240 mg/m2 of doxorubicin) or higher
doses (i.e. cumulative doses > 240 mg/m2 of doxorubicin or
360 mg/m2 of epirubicin) [96]. The improvement in the risk
of recurrence, breast cancer or overall mortality was present
only with the use of higher cumulative doses of anthracy-
clines (Table 2). This suggests that a real difference between
these regimens exists but is limited to anthracycline regi-CG) overview results comparing adjuvant chemotherapy (CT)
t cancer mortality Overall mortality
.79, 95%CI
lute gain: 6.5%
RR: 0.84, 95%CI
Absolute gain: 5%
.76, 95%CI
lute gain: 6.2%
RR: 0.84, 95%CI
Absolute gain: 4.7%
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8 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 3 –2 2mens containing three agents (e.g. CEF, CAF) and given for at
least six cycles. Standard dosing of anthracycline-based ther-
apy (four cycles of a two-drug regimen, e.g. 4AC) seems to be
equivalent to CMF.4.2.1. Anthracyclines versus Anthracylines + taxane based
therapy
The role of taxane-base CT as adjuvant treatment of EBC is an
extensively studied but still controversial issue. We currently
have 21 clinical trials of first-generation taxanes, several
pooled analyses, meta-analyses, and since 2012 the role of
these agents is also evaluated in the analysis of the EBCTCG
overview.
Some of the key first-generation taxane trials are pre-
sented in Table 3. When analysing the 12 first-generation tri-
als using low-strength anthracycline reference regimens,
eight suggest a benefit in terms of DFS for the taxane regimen
(CALGB 9344; NSABP B-28; the MD Anderson Neoadjuvant
Trial; FinHER; BCIRG 001; HORG; GEICAM 9805; US Oncology
Group 9735) and only three of the 10 trials that reported sur-
vival showed a benefit in OS (CALGB 9344, BCIRG 001, and
US Oncology 9735).
Several pooled analyses and meta-analyses have been
undertaken aiming to clarify the benefit of taxane-based ther-
apy (Table 3). Overall they support a modest improvement in
DFS and overall survival (5% and 3% absolute benefit,
respectively) when taxane-based regimens are compared
with standard anthracycline polychemotherapy, irrespective
of the type of taxane, schedule of administration, extent of
nodal involvement and hormone-receptor expression status
[97].
In the EBCTCG 2012 meta-analysis the incorporation of a
taxane into an anthracycline CT regimen resulted in reduc-
tion in the recurrence risk, risk of breast cancer and overall
mortality (Table 3) independently of age, nodal status, tumour
size, tumour grade or ER status.
However, we must underscore that treatment compari-
sons varied greatly, which complicates the analysis. In this re-
gard, the effect of taxanes was analysed taking into account
how the CT regimen in the control group compared with the
non-taxane CT in the taxane group (same, doubled or inter-
mediate). The major effect of these agents was seen in the tri-
als where the same control regimen was used in both arms
(n = 11,167 women) with a reduction in the risk of recurrence,
breast cancer and overall mortality that translated into an
absolute gain of 4.6%, 2.8% and 3.2%, respectively [96]. When
considering this benefit we must acknowledge that in these
trials a ‘week’ anthracycline-based regimen was used and
greater treatment duration was obtained with the additional
four cycles of a taxane to the anthracycline regimen. As a
matter of fact, when the number of cycles in the control
anthracycline regimen was doubled (to mirror the addition
of four cycles of taxanes to anthracyclines in the experimen-
tal arm) there was little difference in recurrence, breast can-
cer or overall mortality (Table 3).4.2.2. HER2 positive breast cancer
The optimal anti-HER2 adjuvant treatment will be addressed
below
Table 3 – Adjuvant taxane trials in early breast cancer (EBC).
Study Population Median
follow-up
(months)
Treatment DFS (P-value) OS (P-value)
‘‘Low-strength’’ sequential anthracycline
CALGB 9344 Node-positive EBC
(n = 3170)
69 AC · 4 versus AC · 4 –
Pac · 4
7 years: 64% versus
58% (HR: 0.83;
P = 0.001)
7 years: 74% versus
68% (HR: 0.82,
P = 0.01)
NSABP B-28 Node-positive EBC
(n = 3060)
34 AC · 4 versus AC · 4 –
Pac · 4
5 years: 76% versus
72%; (HR: 0.83;
P = 0.002)
5 years: 85% versus
85% (HR: 0.93;
P = 0.46)
MDACC EBC (n = 524) 60 FAC · 8
Pac · 4 – AC · 4
86% versus 83% (HR:
0.70; P = 0.009)
NR
NSABP B-27 T1–T3 operable BC
(n = 2411)
102 S! AC! Doc versus
S! AC
AC! S! Doc versus
S! AC
71% versus 68% (HR:
0.92; P = 0.29)
70% versus 68% (HR:
0.92; P = 0.29)
83% versus 82% (HR:
0.93; P = 0.46)
82% versus 83% (HR:
0.97; P = 0.7)
‘‘Low-strength’’ concurrent anthracyclinea
BCIRG-001 Node-positive EBC
(n = 1491)
124 DAC · 6
FAC · 6
62% versus 55%,
P = 0.0043
76% versus 69%,
P = 0.002
GEICAM 9805 Node-negative EBC
(n = 1060)
77 DAC · 6
FAC · 6
87.8% versus 81.8%
(HR: 0.68; 95%CI;
P = 0.01)
95.2% versus 93.5%
(HR: 0.76; 95%; P = NS)
‘‘Standard strength’’ sequential anthracycline*
GEICAM 9906 Node-positive EBC
(n = 1246)
66 FECq3w · 6
FEC · 3 – Pac · 8w
78% versus 72% (HR:
0.74; P = 0.006)
90% versus 87% (NR;
P = 0.11)
PACS 01 Node-positive EBC
(n = 1999)
60 FECq3w · 6
FEC · 3 – Doc · 3w
78% versus 73% (HR:
0.82;
P = 0.034)
91% versus 87% (HR:
0.73; P = 0.014)
WGSG/AGO
EC-Doc Trial
1–3 Positive lymph
node (n = 2011)
41 4 · EC – 4 · Doc
6 · FEC100
6 · CMFb
Estimated 5 years EFS
91% versus 85% (HR:
0.58, P = 0.004)
Estimated 5 years OS
95% versus 91%
(P = 0.03)
Meta-analysis
Meta-analysis 13 Studies EBC
(n = 22,903)
– – HR: 0.83 (95%CI, 0.79–
0.87; P < 0.00001)
HR: 0.85 (95%CI, 0.79–
0.91; P < 0.00001)
EBCTCG overview – taxane-plus-anthracycline
versus anthracycline-based regimen
Results for all trials that test taxane
effect (n = 44,000)
Distant recurrence RR: 0.87
Any recurrence RR: 0.86
(P = 0.00001)
BC mortality RR: 0.87
(P = 0.00001)
Other mortality RR: 0.99
Overall mortality RR: 0.89
(P = 0.0001)
Unconfounded trialsa
(taxane versus control group)
8-year recurrence:
30.2% versus 34.8%
(absolute gain 4.6%)
8-year BC mortality:
21.1% versus 23.9%
(absolute gain 2.8%)
8-year overall mortality
23.5% versus 26.7%
(absolute gain 3.2%)
Counfounded trialsa
(taxane versus control group)
8-year recurrence:
19.2% versus 22%
(absolute gain 2.9%)
8-year BC mortality:
10.1% versus 11.5%
(absolute gain 1.4%)
8-year overall mortality
11.2% versus 12.4%
(absolute gain 1.2%)
FEC, cyclophosphamide, epirubicin, and fluorouracil; AC, doxorubicin and cyclophosphamide; Pac, paclitaxel; FAC, fluorouracil, doxorubicin
and cyclophosphamide; Doc, docetaxel; S, surgery; DAC, docetaxel, doxorubicin, cyclophosphamide; EC, epirubicin and cyclophosphamide;
CMF, cyclophosphamide, methotrexate, and fluorouracil.
a Anthracycline-based adjuvant breast cancer regimens are categorized into ‘standard-strength’ and ‘low-strength’ regimens based on
cumulative doses of doxorubicin >240 mg/m2 and epirubicin >360 mg/m2. Example: standard strength: FEC100; FEC90; CEF; CAF:A75 or E100
followed by CMF; reduced strength: FEC75; FEC60; FEC50; FAC; AC; EC.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 3 –2 2 94.3. Should anthracyclines be avoided in the adjuvant
setting?
Anthracyclines are amongst the most active chemotherapeu-
tic agents for the treatment of breast cancer. Multiple trials in
the past two decades demonstrated that anthracycline-based
chemotherapy was associated with lower rates of breast can-
cer recurrence and improved survival when compared withnon-anthracycline chemotherapy regimens, such as CMF
[96]. However, these agents are associated with increased risk
of cardiovascular complications, dependent on cumulative
dose and schedule, and are often irreversible.
The benefit of taxanes when incorporated into the adju-
vant setting for women with newly diagnosed breast cancer
was analysed in several trials and has been discussed above.
It is, however, unknown whether the benefit seen from add-
10 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 3 –2 2ing a taxane in the adjuvant setting will obviate the need for
anthracyclines in a subset of patients, since the great major-
ity of studies evaluated the addition of a taxane to an anthra-
cycline regimen and not its replacement. A phase III
randomised trial, the US Oncology Research Trial 9735 [98],
enrolled 1016 women with stages I–III HER2-negative breast
cancer and randomly assigned therapy with four cycles of
AC or four cycles of docetaxel plus cyclophosphamide (TC).
With a median follow-up of 7 years, TC resulted in a signifi-
cantly higher DFS (81% versus 75%) and OS (87% versus
82%). However, how the TC regimen compares with stronger
anthracycline-based regimens such as FEC/FAC and with
third-generation regimens, which incorporate both an
anthracycline and taxane, is still unknown. Therefore, most
international guidelines continue to recommend an anthra-
cycline- and taxane-containing regimen for most women,
particularly those with higher-stage tumours, and for those
with triple-negative or HER2+ BC, unless there are clear con-
traindications for the use of anthracyclines [13].
The role of anthracycline regimens in the HER2+BC is also
a matter of intense research. Several CT regimens used with
trastuzumab have been evaluated in large prospective stud-
ies, and historically anthracyclines have been considered crit-
ical for the management of HER2+ BC. A number of studies
from the pre-trastuzumab era support this concept. Retro-
spective subset analyses of anthracycline-based adjuvant CT
studies have suggested that the major benefit for these regi-
mens is seen in HER2-over-expressing tumours [99]. The value
of HER2 and TOP2A as predictive markers of response to
anthracycline-based therapy has been extensively studied.
In the meta-analysis by Di Leo et al., although HER2 amplifica-
tion and combined TOP2A amplification and deletion had
some value in prediction of responsiveness to anthracy-
cline-based therapy, the overall findings did not support the
routine use of TOP2A to select the adjuvant CT regimen in this
patient population [78].
With the advent of trastuzumab, concerns have been
raised regarding the use of anthracycline-based regimens in
HER2+ early BC due to potential cardiotoxicity. Previous or
concurrent anthracyclines are a risk factor for trastuzumab-
related cardiotoxicity. Notwithstanding the increased inci-
dence of cardiac events, these still remain in very acceptable
ranges for all types of CT regimens used in the adjuvant set-
ting. Rates of severe congestive heart failure in adjuvant trials
ranged between 0.4% and 3.5%, depending on the regimen
and schedule used.
Combining trastuzumab with a non-anthracycline-con-
taining CT regimen was evaluated in the BCIRG 006 trial with
the aim of investigating whether the association of trast-
uzumab, carboplatin and docetaxel could be better tolerated
and superior in terms of efficacy compared with an anthracy-
cline-based schedule [79]. At a median follow-up of
65 months, the differences in DFS and OS between ACTH
and TCH, although not statistically significant, were numeri-
cally different, with a trend favouring the anthracycline-con-
taining regimen. The trial hypothesis that TCH was superior
to ACTH was not proven and, since the study was not pow-
ered to detect equivalence between ACTH and TCH, this con-
clusion cannot be drawn. With respect to adverse events, the
differences were significantly lower rates of severe (grade )neutropenia (66% versus 63%) and leucopaenia (48% versus
60%) but significantly higher rates of anaemia (6% versus
3%) and thrombocytopenia (6% versus 2%) for TCH and a
higher incidence of congestive heart failure (2% versus
0.4%), subclinical and sustained loss of mean left ventricular
ejection fraction (18.6% versus 9.4%) for ACTH. Based on this
trial alone, TCH can only be considered an alternative treat-
ment for patients with contraindications to anthracyclines
(pre-existing cardiac conditions, borderline ejection fraction
at baseline, or prior anthracycline exposure) while anthracy-
cline-based regimens remain the standard of care.
Findings suggest that the more dramatic risk reduction
when adding trastuzumab to CT is observed when using some
concurrent CT and trastuzumab, and employing both anthra-
cycline and a taxane.
4.4. Dose-dense adjuvant chemotherapy
The introduction of granulocyte-colony-stimulating factors
has allowed the administration of CT in the dose-dense ap-
proach, thought to have higher efficacy based on mathemat-
ical models of human breast cancer growth [100]. The
pivotal trial CALGB9741 [101] has shown significant improve-
ment in DFS and OS with dose-dense concurrent AC followed
by paclitaxel in women with node-positive EBC. Several trials
with dose-dense regimens have shown similar results, as
shown in a systematic review and meta-analysis of these
studies [102] with HR of death 0.85 (95%CI = 0.77–0.93) and
HR of relapse or death 0.81 (95%CI = 0.75–0.88). Another
important finding was that the benefit was seen only in hor-
monal-receptor-negative disease. There was no statistically
significant increase in adverse events. The concern about
these results is related to the design of these trials that did
not evaluate the same agents and doses in the conventional
arm as in the investigational arm. Further prospective data
will help to clarify which patients should be selected for this
approach. At the moment these regimens have been mainly
used in high-risk disease with features of aggressive biology.
4.5. Sequential versus combination regimens
Sequential single-agent doxorubicin and cyclophosphamide
did not improve outcome compared with combination AC
[103]. Sequential versus concurrent use of anthracyclines
and taxanes in EBC has been evaluated in three studies: CAL-
GB 9741, BIG 2-98 and NSABP B-38.
The first study, CALGB 9741 [101], randomised 2005 female
patients, with node-positive disease, to sequential
A · 4! T · 4! C · 4, every 3 weeks; A · 4! 3 T · 4! C · 4,
every 2 weeks with filgrastim; concurrent AC · 4! T · 4,
every 3 weeks or AC · 4! T · 4, every 2 weeks with filgrastim.
Dose-dense treatment was associated with improved DFS and
OS, with no increase in toxicity.
In the BIG-2-98 [104] study 2887 patients, also with node-
positive disease, were randomised to sequential A · 4!
CMF · 3 (sequential control); concurrent AC · 4! CMF · 3
(concurrent control); sequential A!T · 4! CMF · 3 (sequen-
tial experimental); concurrent AT · 4! CMF · 3 (concurrent
experimental). The updated analysis [105] revealed that
sequential docetaxel was associated with significant
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concurrent AT.
Preliminary results of NSABP B-38 were recently presented
[106]. The trial randomised 4894 women (65% node-positive)
to dose-dense ACT, dose-dense AC followed by the combina-
tion of paclitaxel and gemcitabine (ACTG), or TAC. Five-year
DFS and OS were similar between groups, but the TAC regi-
men was associated with more grade 3/4 toxicity, namely feb-
rile neutropenia and diarrhoea. Based on the tolerability
profile, and on the possible higher efficacy, sequential anthra-
cycline–taxane-based regimens are preferred to combination
regimens.
4.6. Are there predictive biomarkers to help select the
optimal regimen?
Identification of markers that predict chemosensitivity in BC
is a research priority. Several approaches and technologies
have been used to identify these predictive markers. The
aim is to answer two questions: (a) can we use gene signa-
tures to identify tumours, which are more likely to respond
to chemotherapy? and (b) when chemotherapy is indicated,
what is the optimal chemotherapy regimen for a specific tu-
mour or group of tumours?
4.6.1. Markers predicting general chemosensitivity
Since patients with poor prognosis disease defined by first-
generation signatures have tumours with high expression of
proliferation-related genes, and cytotoxic agents target the
proliferating fraction of tumours, the finding that first-gener-
ation prognostic signatures also predict benefit from conven-
tional multidrug CT regimens is not surprising [45,107–110].
With respect to OncotypeDx, two retrospective studies
have reported its predictive value for chemosensitivity
[32,111]. In the NSABP trial B-20, 651 patients with node-neg-
ative, hormone-receptor-positive tumours were randomised
to tamoxifen alone (n = 227) or tamoxifen plus CT (methotrex-
ate–fluorouracil or CMF) (n = 424) [32]. A high recurrence score
predicted benefit from CT [hazard ratio (HR) = 0.26; 95%
CI = 0.13–0.53], with little or no benefit from CT in the low
and intermediate recurrence score groups. The predictive va-
lue of the OncotypeDx was also assessed in a subset of pa-
tients more than 50 years old with node-positive hormone-
receptor-positive tumours included in the SWOG 8814 trial
[111]. In this trial, patients were randomised to receive either
tamoxifen alone (n = 361); CAF followed by tamoxifen for
5 years (n = 566); or concurrent CAF and tamoxifen (n = 550).
The 21-gene recurrence score was assessed in 367 of these pa-
tients. The addition of CT to tamoxifen resulted in no differ-
ence in DFS or OS in the low recurrence score group, but a
clear benefit in DFS and OS in the high recurrence score
group. There appeared also to be a benefit for patients in
the intermediate recurrence score group, but the confidence
intervals were wide due to the small sample size.
This signature was assessed in a series of 167 patients with
tumours >5 cm or clinically positive nodes and has also been
suggested to predict the response to neoadjuvant CT [112].
Pathological complete response (pCR) after neoadjuvant CT
was used as a surrogate for chemosensitivity and in this trialonly patients with a bad signature achieved a pCR of 20% (29/
144). None of the patients with a good signature (n = 144)
achieved a pCR (0/23). The authors concluded that patients
with a good signature would be unlikely to respond to CT.
4.6.2. Markers predicting drug-specific chemosensitivity
There are currently no biomarker predictors of response to
specific cytotoxic agents. There are several reasons for the
apparent inability to develop these predictive factors, namely:
(a) resistance or response to therapies may be caused by a
functional alteration in only a few genes and this may not
manifest itself as a detectable signal in the complex tran-
scriptomic landscape of a tumour; (b) tumours are often com-
posed of a mosaic of genetically heterogeneous clonal
subpopulations harbouring numerous private genetic aberra-
tions (that is, aberrations found in a single clone of a tumour
[31,113]. These private genetic aberrations may be the drivers
of resistance to therapy in a subpopulation and would not be
detected by microarrays that survey the average expression
profile of the entire tumour.
The Topoisomerase II Alpha Gene Amplification and Pro-
tein Overexpression Predicting Efficacy of Epirubicin (TOP)
trial (NCT00162812) led to the development of the anthracy-
cline-based score (A-score), which combines three predictive
signatures: a TOP2A gene signature and signatures related
to tumour invasion and immune response [74]. Analysis of
the predictive power of the A-score was performed in the
EORTC 10994/BIG (Breast International Group) 00-01
(NCT00017095) trial and from ER-negative patients from the
Randomised Clinical Trial to Evaluate the Predictive Accuracy
of a Gene Expression for Stage I–II Breast Cancer
(NCT00336791). Both studies revealed its high negative predic-
tive value (0.98, 95%CI 0.90–1.00) [74] suggesting, if validated,
its potential clinical use for identification of patients who
are unlikely to benefit from anthracyclines.5. What is the optimal adjuvant endocrine
treatment?
5.1. Tamoxifen 5 years
Endocrine therapy (ET) is one of the most effective treatments
in women with endocrine responsive breast cancer. Tamoxi-
fen has been the mainstay endocrine agent for both pre-
and postmenopausal women. Updated analyses [114] of the
EBCCTG overview assessed long-term outcomes among
21,475 women with EBC in trials of 5 years of tamoxifen com-
pared with observation or placebo. In oestrogen-receptor- (ER-
)positive disease, 5 years of tamoxifen significantly reduced
recurrence rates throughout the first 10 years, independently
of progesterone receptor status, nodal status, or use of CT: rel-
ative risk (RR) 0.53 during years 0–4 and RR 0.68 during years
5–9 [both 2P < 0.00001]. For marginally ER-positive disease
there was also an important risk reduction (RR 0.67). More
importantly there was a reduction in breast cancer mortality
by about a third throughout the first 15 years (RR 0.71 during
years 0–4, 0.66 during years 5–9, and 0.68 during years 10–
14; P < 0.0001).
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premenopausal patients
The standard adjuvant hormonal therapy in premenopausal
women with ER-positive disease remains tamoxifen alone
for 5 years, but benefit has also been shown with the use of
luteinising-hormone-releasing (LHRH) agonists specifically
in the absence of CT. Several studies have been conducted
testing LHRH agonists alone, combined with tamoxifen, che-
motherapy or both. In the EBCTCG overview [115] 8000 pa-
tients randomised to ovarian function suppression (OFS) or
ablation by surgery/radiation had reduced recurrence and
breast cancer mortality, but the benefit was seen mainly in
the absence of other systemic treatments. An individual pa-
tient data meta-analysis [116] of 16 trials using LHRH identi-
fied 9022 women with ER+ disease and assessed recurrence
rate, breast cancer mortality and overall mortality. While
LHRH agonists alone did not have a significant effect, adding
these agents to CT, to tamoxifen or both, significantly reduced
recurrence by 12.7% (P = 0.02) and death after recurrence by
15.1% (P = 0.03). Furthermore, the benefit of LHRH agonists
after CT was seen in women younger than 40 years, but not
in older premenopausal women. However, the data do not an-
swer the question of whether LHRH agonist is useful only
when amenorrhoea is not achieved with CT, an event that
has been associated with worse outcome in some trials
[117,118].
Recently a guideline from Cancer Care Ontario was pub-
lished and endorsed by ASCO [119] conducting a systematic
review of available literature. The guideline does not recom-
mend the routine use of OFS added to chemotherapy, tamox-
ifen or a combination of both. It does acknowledge as a major
difficulty in assessing its efficacy the fact that ovarian sup-
pression has not been compared with current CT regimens
(e.g. anthracyclines or anthracyclines/taxanes), which deems
the benefit of these agents unclear. For chemical suppression
the guideline does suggest the use of monthly injections.
The role of aromatase inhibitors (AIs) in premenopausal
women was assessed in the ABCSG-12 trial [120] which ran-
domised 1803 patients to receive goserelin monthly plus
tamoxifen or anastrozole, with or without zoledronic acid
for 3 years. There was no significant difference in DFS be-
tween the anastrozole and tamoxifen groups (HR = 1.10; CI
0.78–1.53), but the trial was relatively small to answer this
secondary objective. Till now AIs combined with OFS are only
recommended in premenopausal patients if tamoxifen is
contraindicated. To better understand the role of aromatase
inhibitors, as well as OFS in this setting, results from the stud-
ies TEXT, SOFT and PROMISE are eagerly awaited.5.2.1. Aromatase inhibitors
For postmenopausal patients the aromatase inhibitors anas-
trozole, letrozole and exemestane have been extensively
studied in adjuvant setting as upfront therapy for 5 years,
‘‘switch’’ strategy of initial tamoxifen for 2–3 years followed
by an AI 2–3 years, the reverse sequence, or as an extended
treatment after 5 years of tamoxifen (see Table 4) [121–129].
The meta-analysis of the adjuvant trials [130] analysed a co-
hort of 9856 patients where AI upfront therapy was comparedwith standard tamoxifen treatment, showing a significant
2.9% absolute decrease in recurrence and a non-significant
absolute 1.1% decrease in breast cancer mortality. A second
cohort comprising 9015 patients compared the switch strat-
egy with standard tamoxifen treatment and showed a signif-
icant absolute decrease in recurrence and in breast cancer
mortality of 3.1% and 0.7%, respectively. Current ASCO [131]
and European Guidelines [132] recommend the incorporation
of AIs in the endocrine treatment plan as switch (2–3 years) or
upfront therapy strategy (5 years). For patients who have
completed 5 years of tamoxifen the addition of an AI for a fur-
ther period of 2–5 years is recommended, especially for pa-
tients with node-positive disease. On the other hand,
5 years of tamoxifen alone is still a viable option for certain
patients at very low risk of recurrence.
The choice of endocrine treatment and the timing for AI
treatment is nowadays based on the toxicity profile of these
drugs compared with tamoxifen, general health issues of
each individual and the risk of relapse. A recent meta-analy-
sis [133] on safety reports from major adjuvant trials found
that AI therapy was associated with a higher risk for cardio-
vascular disease (HR, 1.2) and bone fracture (HR, 1.48) than
tamoxifen, but a lower risk for venous thromboembolism
(HR, 0.53) and uterine cancer (HR, 0.32). Overall these risks
were low, around 2% of patients, and fractures only occurred
in fewer than 10% of all patients. Additional data from a pop-
ulation-based study [134] evaluating 44,000 women with
breast cancer and age-matched women without breast can-
cer, have shown that breast cancer patients on ET had a lower
risk for both myocardial infarction and ischaemic stroke than
those who did not have breast cancer. No differences were
seen between AI therapy and tamoxifen therapy in the risk
for myocardial infarction or stroke, but AI therapy was asso-
ciated with a higher risk for any fracture (mainly hip frac-
tures). Guidelines [131,132] recommend surveillance of bone
mineral density during AI treatment, and calcium and vita-
min D supplementation or a bisphosphonate depending on
the result.
5.3. Extended ET treatment
Because the risk of recurrence in hormone-receptor-positive
disease still remains after the first decade [135], clinicians
and researchers have been questioning the benefit of ex-
tended tamoxifen treatment beyond 5 years. Three prospec-
tive trials addressed this question, randomising patients
after 5 years of tamoxifen treatment to additional 5 years of
treatment or placebo (NSABP-B14 [136], aTTom trial [137]
and ATLAS trial [138]). Except for the NSABP B14 trial, these
studies together with EBCCTG [114] have shown benefit for
extended tamoxifen. However, balance with side effects has
to be considered as extended treatment is associated with in-
creased incidence of endometrial cancer, which is 2.3-fold
with 5 years of tamoxifen and 4-fold with 10 years [114]. On
the other hand, there is some evidence that tamoxifen has
a favourable effect in lipid profile [139–141]. ATLAS results
suggest some protection against ischaemic heart disease
and certainly no increase in stroke deaths. In the EBCCTG
overview the non-significant excess of stroke deaths was bal-
anced by a non-significant shortfall in cardiac deaths with lit-
Table 4 – Trials of adjuvant endocrine therapy.
Study Treatment arms/
population (n)
Median follow-up Recurrence Mortality
Tamoxifen 5 years
Overview 2011 (W164) TAM 5 years versus
no
TAM 10,645 ER+
15 years RR = 0.53 [SE 0.03]
years 0–4
RR = 0.68 [SE 0.06]
years 5–9
2P < 0.00001
RR = 0.97 [SE 0.10]
years 10–14
RR = 0.71 [SE 0.05]
years 0–4
RR = 0.66 [SE 0.05]
years 5–9
RR = 0.68 [SE 0.08]
years 10–14
P < 0.0001
OFS
Overview 2005 [115] 8000 ER+/ER
unknown, <50 years,
OFS
LHRH– 3408
5 years 15 years gain 4.3% (SE
1.9)
2P < 0.00001
15 years gain 3.2% (SE
2.0)
2P = 0.04
Meta-analysis [164] 11,906
Premenopausal
6.8 years No systemic treatment
versus LHRH:
HR 0.72 (95%CI 0.49–
1.04), P = 0.08
CT versus LHRH:
HR 1.04 (95%CI 0.92–
1.17), P = 0.52
CT versus
LHRH + TAM:
HR 0.90 (95%CI 0.75–
1.08), P = 0.25
Addition to TAM:
HR 0.85 (95%CI 0.67–
1.09), P = 0.20
Addition to CT ± TAM:
HR 0.88 (95%CI 0.77–
0.99), P = 0.04
No systemic treatment
versus LHRH:
HR 0.82 (95%CI 0.47–
1.43), P = 0.49*
CT versus LHRH:
HR 0.93 (95%CI 0.79–
1.10), P = 0.40a
CT versus
LHRH + TAM:
HR 0.89 (95%CI 0.69–
1.15), P = 0.37a
Addition to TAM:
HR 0.84 (95%CI 0.59–
1.19), P = 0.33a
Addition to CT ± TAM:
HR 0.85 (95%CI 0.73–
0.99), P = 0.04*
AIs 5 years
ATAC [164] TAM 5 years versus
ANA 5 years
3116/3125
120 months HR = 0.91 (95%CI 0.83–
0.99)
P = 0.04
0.97 (95%CI 0.88–1.08)
P = 0.6
BIG 1.98 [164] TAM 5 years versus
LET 5 years
2459/2463
76 months HR = 0.88 (95%CI 0.78–
0.99)
P = 0.03
HR = 0.87 (95%CI 0.75–
1.02)
P = 0.08
TEAM [164] EXE 5 years versus
TAM 2–3 years
followed EXE 2–
3 years
4868/4898
5.1 years HR = 0.97 (0.88–1.08)
P = 0.60
HR = 1.00 (0.89–1.14)
P > 0.9
Meta-analysis [164] Cohort 1
AIs initial
monotherapy versus
TAM
9856
5.8 years 9.6% AI versus 12.6%
TAM
2.9% absolute
decrease (SE 0.7%)
2P < .00001
4.8% AI versus 5.9%
TAM
1.1% (SE = 0.5%)
absolute decrease
2P = 0.1
MA.27 [6] EXE 5 years versus
ANA 5 years
7576
4.1 years HR = 1.02 (95%CI 0.87–
1.18)
P = 0.85
HR = 0.93 (95%CI 0.77–
1.13)
P = 0.46
AIs and tamoxifen in switching strategies
BIG 1.98 [129] LET 5 years
TAM 2 years followed
by LET 3 years
LET 2 years followed
by TAM 3 years
1546/1548/1540
71 months HR = 1.05 (95%CI 0.84–
1.32)
HR = 0.96 (95%CI 0.76–
1.21)
HR = 1.13 (95%CI 0.83–
1.53)
HR = 0.90 (95%CI 0.65–
1.24)
ABCSG-8/ARNO 95 [125] TAM 5 years versus
Tam f 2 years
followed by ANA for
3 years
28 months HR = 0.60 (0.44–0.81)
P = 0.0009
P = 0.16
(continued on next page)
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Table 4 – (Continued)
Study Treatment arms/
population (n)
Median follow-up Recurrence Mortality
ITA [122] TAM 5 years versus
Tam f 2 years
followed by ANA
128 months HR = 0.64 (0.44–0.94)
P = 0.023
HR = 0.72 (0.44–1.17)
P = 0.3
IES [124](164)(164) (164) TAM 5 years versus
Tam f 2–3 years
followed by EXE 2–
3 years
55.7 months HR = 0.76 (95%CI 0.66–
0.88)
P = 0.0001
HR 0.85 (95%CI 0.71–
1.02)
P = 0.08
Meta-analysis [130] Cohort 2
AIs T after 2–3 years
of TAM versus TAM
9015
3.9 years 5.0% AI versus 8.1%
TAM
3.1% absolute
decrease (SE 0.6%)
2P < .00001
1.7% AI versus 2.4%
TAM
0.7% (SE = 0.3%)
absolute decrease
2P = 0.2
Extended treatment beyond 5 years
ATLAS [138] TAM 5 years versus
TAM 10 years
3428/3418
NR RR = 0.90 (95%CI 0.79–
1.02) 5–9 years
RR = 0.75 (95%CI 0.62–
0.90) later years
RR: 0.84, 95%CI 0.76–
0.94; P = 0.002 in ER+
RR = 0.97 (95%CI 0.79–
1.18) 5–9 years
RR = 0.71 (95%CI 0.58–
0.88) later years
639 deaths versus 722
deaths, P = 0.01 in ER+
NSABP-B14 [136] TAM 5 years versus
TAM >5 years
579/593
7 years DFS = 82% TAM
5 years versus 78%
TAM >5 years
P = .03
OS7Y = 94% TAM
5 years versus 91%
TAM >5 years
P = .07
aTTOM [137] TAM 5 years versus
TAM 10 years
6934
4.2 years 415 TAM 5 years
versus 442
recurrences TAM
10 years
RR = 0.94 (95%CI 0.81–
1.09)
P = 0.4
NA
MA.17 [143] TAM 5 years followed
LET 5 years
versusTAM 5 years
2594/2593
30 months HR = 0.58 (95%CI 0.45–
0.76)
P < .001
HR = 0.82(95%CI 0.57–
1.19)
P = 0.03
NSABP-B33 [164] TAM 5 years followed
EXE 5 years versus
TAM 5 years
779/786
30 months DFS 4 years 91%
versus 89%
RR = 0.68 (P = 0.07)
16 deaths versus 13
P = 0.1
ABCSG-6a [165] TAM 5 years followed
ANA 3 years versus
TAM 5 years
469/387
62 months HR = 0.62 (95%CI 0.40–
0.96)
P = 0.031
HR = 0.89 (95%CI 0.59–
1.34)
P = 0.57
AI, aromatase inhibitor; DFS, disease-free survival; ER+, estrogen-receptor-positive patients; HR, hazard ratio; RR, event rate ratio; OS, overall
survival; TAM, tamoxifen; LET, letrozole; EXE, exemestane; ANA, anastrozole; LHRH, luteinizing-hormone-releasing agonists; OFS, ovarian
function suppression.
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cent study [142], with a median follow up of 10.1 years, as-
sessed the long-term benefits of 5 years versus 2 years of
tamoxifen use in a large randomised trial of EBC women more
than 50 years of age. Follow-up strategies included matching
trial subjects with death data from the British National Health
Service Information Center. Besides the well-known positive
efficacy of tamoxifen, this study revealed a nearly statistically
significant reduction in cardiovascular deaths (HR, 0.79;
P = 0.08) with longer tamoxifen, and in women of 50–59 years
there was an even greater reduction in cardiovascular events(HR, 0.65; P = 0.005; P = 0.046 for interaction between age and
treatment groups).
In postmenopausal women extended use of AIs after
5 years of tamoxifen has shown improvement in DFS (see Ta-
ble 4), and in one study, the MA-17 trial [143], an improvement
in OS was also seen in node-positive patients. It is not known
if longer use of AIs (more than 5 years) will increase outcomes
without compromising safety, and it is not recommended un-
til mature data from MA.17R and NSABP B-42 trials are avail-
able. The best regimen of ET for postmenopausal patients and
the duration of ET treatment are still unanswered questions.
Table 5 – Phase III trials of adjuvant trastuzumab in patients with HER2-positive early breast cancer (EBC)
Study Population Median
follow-up
(months)
Treatment DFS (P-value) OS (P-value) Cardiac
dysfunction
(%)
HERA [156] Node-positive or
node-negative
high-risk EBC
after completion
of standard CT
(n = 5.090)
96 No additional
therapy
H 1 year
H 2 year
HR = 0.76,
P < 0.0001
HR = 0.76,
P = 0.0005
0.8
3.7
NSABP B-31/
NCCTG N9831
[157]
Node-positive
Node-negative
high-risk EBC
(n = 4046)
100.8 AC!Pac
AC!Pac!H
62.2%
73.7% (P < 0.001)
HR = 0.6
75.2%
84.0%
(P < 0.0001)
HR = 0.63
NCCTG
N9831 [161]
Node-positive
Node-negative
high-risk EBC
(n = 1.944)
63.6 AC!PacH
AC!Pac!H
84% (5 years)
80% (P = 0.0216)
HR = 0.77
NR
NR
17
14
BCIRG 006 [79] Node-positive
Node-negative
high-risk EBC
(n = 3,222)
65 AC!Doc
AC!Doc-H
Doc–Carb–H
75%
84% HR = 0.64
(P < 0.001 versus
CT)
81% HR = 0.75
(P < 0.04 versus
CT)
87%
92% HR = 0.63
(P < 0.001
versus CT)
87%
HR = 0.77
(P < 0.038
versus CT)
9.0
18.1
8.6
PACS-04 [159] Node-positive
EBC
47 FEC or Epi–Doc
FEC or Epi–Doc!H
1 year
78% (3 years)
81% (P = 0.41)
96% (3 years)v
95% (P = 2.38)
2.2
4.2
FinHER [158] Node-positive
Node-negative
high-risk EBC
(n = 232)
62 Doc or Vin !FEC
Doc or Vin !FEC–H
73.3%
83% HR = 0.65
(P = 0.12)
82.3%
91.3% (5 years)
HR = 0.55
(P = 0.094)
Meta-analysis
2012 [160]
All trials included HR: 0.60; 95%
P < 0.00001
HR: 0.66; 95%
P < 0.00001
FEC, cyclophosphamide, epirubicin, and fluorouracil; AC, doxorubicin and cyclophosphamide; Pac, paclitaxel; Doc, docetaxel; S, surgery; H,
herceptin; Carb, Carboplatin; Vin, vinorelbin; Epi, epirubicin.
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response to treatment
Adherence to ET is a concern in patients with EBC as it is be-
lieved to impact on the outcome; however, the association be-
tween non-adherence and breast cancer mortality is not
proven. In ET studies patients are considered to be adherent
to treatment if P80% of prescribed doses are taken, but the
best tool for measurement of adherence is not yet defined,
and has varied among studies. It has been reported that
adherence to tamoxifen falls to 50% during the course of ther-
apy [144]. Non-adherence to anastrozole has been reported to
occur in 1/3 of patients [145]. In a recent population-based
study of 8769 patients with BC [146], 32% discontinued treat-
ment with tamoxifen or an AI over the 4.5-year follow-up per-
iod, and among those who continued 28% were non-adherent.
Younger women were at high risk of non-adherence being
50% more likely to discontinue therapy and 40% more likely
to be non-adherent (P < 001).
Among patients taking AIs the musculoskeletal toxicities
are the main reason for treatment discontinuation/non-
adherence [147–149]. Predictive factors of these adverse ef-fects have been studied, but have not been consistent among
studies. A retrospective exploratory analysis from the ATAC
trial has shown that previous hormone replacement therapy,
previous CT and obesity were risk factors for the development
of joint symptoms. A recent exploratory analysis from a pro-
spective study, the Exemestane and Letrozole Pharmacoge-
netics (ELPh) clinical trial [150], found that younger age and
prior taxane-based CT were associated with a greater likeli-
hood of treatment discontinuation, but prior tamoxifen ther-
apy, prior hormone replacement therapy and body mass
index were not predictors. One third of patients prematurely
discontinued adjuvant AI therapy in this study, but it was also
seen than more than one third of patients who switched
drugs tolerated the second AI, confirming previous results
[151].
There is no evidence to demonstrate differences in efficacy
and toxicity among AIs. Anastrazol has shown efficacy simi-
lar to that of letrozol in the MA.27 trial [152]. The results from
the FACE trial comparing two non-steroidal AIs, letrozole and
anastrozole, are awaited.
The main predictors of response to hormonal treatment
are oestrogen and progesterone receptors [114]. There is no
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sponses to tamoxifen or AIs [129,153]. New genomic tools
such as Oncotype DX and PAM50 [30,154] have been predictive
of tamoxifen treatment, but their use in clinic has been
mainly as a prognostic tool.
Recently an exploratory analysis from the BIG 1-98 trial
[155] of 2599 patients treated with tamoxifen monotherapy
or letrozol monotherapy, with a 12-year follow-up, showed a
significant interaction effect between histology subtype and
degree of benefit to letrozole over tamoxifen, with greater
benefit being seen with letrozol in women with lobular carci-
nomas compared with invasive ductal carcinomas. Although
these data need further validation, it restores confidence in
the use of AI in high-risk lobular tumours.
6. What is the optimal adjuvant anti-HER2
treatment?
For patientswith HER2+ early BC the use of trastuzumab and CT
is well established and evaluated in six adjuvant trastuzumab
randomised clinical trials (Table 5) involving more than
13,000 women: the Herceptin Adjuvant trial (HERA) [156], the
National Surgical Adjuvant Breast and Bowel Project (NSABP)
B-31 trial and the North Central Cancer Treatment Group
(NCCTG) N9831 trial [157], the Breast Cancer International Re-
search Group (BCIRG) 006 trial [79], the Finland Herceptin trial
(FinHER) [158] and the Protocol Adjuvant dans le Cancerdu Sein
(PACS-04) trial [159], and in a 2012 meta-analysis [160].
All trials except PACS-04 yielded an improved DFS (HR be-
tween 0.6 and 0.77) and OS (HR between 0.55 and 0.77) with
the administration of trastuzumab (Table 5).
Cardiac toxicity data from these trials indicate that the
rate is higher when anthracyclines are used and with concur-
rent regimens. Nevertheless, the rates are always low and
clinically acceptable.
The 2012 meta-analysis of eight studies, involving 11,991
patients, assessed the benefits of adding trastuzumab to adju-
vant CT in patients with HER2+ BC [160]. The inclusion of
trastuzumab resulted in an improvement in DFS with an
HR = 0.60 (95%CI 0.50–0.71), regardless of trastuzumab treat-
ment duration or administration schedule (i.e. concurrently
or sequentially with CT) and an improvement in OS with an
HR = 0.66 (95%CI 0.57–0.77).
6.1. Timing of trastuzumab initiation
The decision about whether trastuzumab should be adminis-
tered concurrently or sequentially after the completion of
adjuvant CT as been addressed directly in the N9831 trial.
The second planned interim analysis, with a median follow-
up of 6 years, indicates that although trastuzumab added
sequentially to CT improves DFS, there is a strong trend to-
wards a better outcome with concurrent trastuzumab relative
to sequential administration [161].
In the 2012 meta-analysis the benefit in OS was associated
with concurrent administration [HR 0.64 (95%CI 0.53–0.76)]
but not with sequential treatment of CT followed by single-
agent trastuzumab [HR 0.85 (95%CI 0.43–1.67)] [160]. BCIRG-
006 also support the use of trastuzumab administered concur-
rently with CT in the adjuvant setting [79].6.2. Duration of trastuzumab treatment
One year of trastuzumab is the standard of care in adjuvant
therapy. In the HERA trial a comparison between 1 and 2 years
of adjuvant trastuzumab after CT concluded that 2 years of
treatment was not better than 1 year [162]. The PHARE trial
recruited over 3380 HER2+ patients and randomly assigned
them to receive either 6 months or 1 year of adjuvant trast-
uzumab. The trial results were reported as unable to prove
the non-inferiority hypothesis of 6 months versus 1 year of
adjuvant trastuzumab [163]. In the 2012 meta-analysis trast-
uzumab administered for 12 months was associated with an
improvement in OS [HR 0.67 (95%CI 0.57–0.80)]; although
trastuzumab treatment for 66 months also showed a trend
towards an improvement in OS, it did not reach statistical sig-
nificance [HR 0.55 (95%CI 0.27–1.11)] [160].
Several trials are still ongoing evaluating the optimal dura-
tion and regimen of adjuvant trastuzumab; these might lead
to a different conclusion in the future. The relative benefit
of 6 months versus 1 year of trastuzumab is being evaluated
in the PERSEPHONE trial (which also evaluates sequential ver-
sus concurrent trastuzumab) and the HELLENIC trial (using
only concurrent therapy). The SHORT-HER and SOLD trials
are evaluating 9 weeks versus 12 months of trastuzumab gi-
ven concomitantly with a taxane, similar to the FinHER trial.
7. Conclusions and future perspectives
(Neo)adjuvant systemic therapy has dramatically changed the
natural history of EBC. Together with screening and early
detection, it is responsible for the 30% decrease in mortality
observed since the 1990s.
The stronger effects are seen with biologically targeted
agents such as endocrine and anti-HER2 therapies. Similar
advances are still lacking for the heterogeneous groups of tri-
ple-negative EBC.
Prognostication has been greatly improved in the last dec-
ade, but advances in prediction have been only minimal and
remain a research priority.
New technologies and a better knowledge of the biology of
the different subtypes of BC, as well as an in-depth under-
standing of the mechanism of cancer resistance, will hope-
fully enable us to achieve a true individualised/personalised
medicine in the near future
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